NCT00957554 - Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy | Biotech Hunter

Enrollment

435

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Hypertension

Interventions

DRUG

irbesartan/amlodipine

Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily

DRUG

irbesartan

Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily

Trial Locations (38)

1008

Sanofi-Aventis Investigational Site Number 78801, Tunis

Sanofi-Aventis Investigational Site Number 78812, Tunis

4545

Sanofi-Aventis Investigational Site Number 784-02, Dubai

5000

Sanofi-Aventis Investigational Site Number 78813, Monastir

11340

Sanofi-Aventis Investigational Site Number 48406, México

20000

Sanofi-Aventis Investigational Site Number 50403, Casablanca

27000

Sanofi-Aventis Investigational Site Number 48404, Torreón

44210

Sanofi-Aventis Investigational Site Number 48408, Zapopan

44340

Sanofi-Aventis Investigational Site Number 48402, Guadalajara

72244

Sanofi-Aventis Investigational Site Number 48403, San Luis Potosí City

78200

Sanofi-Aventis Investigational Site Number 48407, San Luis Potosí City

97070

Sanofi-Aventis Investigational Site Number 48401, Mérida

30150-221

Sanofi-Aventis Investigational Site Number 07605, Belo Horizonte

95070-560

Sanofi-Aventis Investigational Site Number 07602, Caxias do Sul

57051-500

Sanofi-Aventis Investigational Site Number 07604, Maceió

15015-210

Sanofi-Aventis Investigational Site Number 07603, São José do Rio Preto

18030-083

Sanofi-Aventis Investigational Site Number 07601, Sorocaba

Unknown

Sanofi-Aventis Investigational Site Number 17001, Barranquilla

Sanofi-Aventis Investigational Site Number 17002, Barranquilla

Sanofi-Aventis Investigational Site Number 17003, Cartagena

Sanofi-Aventis Investigational Site Number 32001, Guatemala City

Sanofi-Aventis Investigational Site Number 32002, Guatemala City

Sanofi-Aventis Investigational Site Number 32003, Guatemala City

Sanofi-Aventis Investigational Site Number 32004, Guatemala City

Sanofi-Aventis Investigational Site Number 32005, Guatemala City

Sanofi-Aventis Investigational Site Number 50401, Casablanca

Sanofi-Aventis Investigational Site Number 50402, Casablanca

Sanofi-Aventis Investigational Site Number 50405, Casablanca

Sanofi-Aventis Investigational Site Number 50404, Rabat

Sanofi-Aventis Investigational Site Number 50406, Rabat

Sanofi-Aventis Investigational Site Number 78805, Aryanah

Sanofi-Aventis Investigational Site Number 78804, La Marsa

Sanofi-Aventis Investigational Site Number 78802, Menzel Bourguiba

Sanofi-Aventis Investigational Site Number 78815, Sousse

Sanofi-Aventis Investigational Site Number 78803, Tunis

Sanofi-Aventis Investigational Site Number 78807, Tunis

Sanofi-Aventis Investigational Site Number 784-001, Abu Dhabi

Sanofi-Aventis Investigational Site Number 86201, Maracaibo